LeeAnn Peluso1, Vincent W Vanek. 1. Surgical Education, St Elizabeth Health Center, Youngstown, OH 44501-1790, USA.
Abstract
BACKGROUND: Obesity is associated with multiple comorbidities, including hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus, obstructive sleep apnea, osteoarthritis, back/extremity pain, gastroesophageal reflux disease (GERD), asthma, and depression. Surgical weight loss can markedly improve if not resolve many of these comorbidities. METHODS: This was a retrospective study of 400 consecutive gastric bypass patients, analyzing postoperative resolution or improvement of obesity-related comorbidities. RESULTS: Mean follow-up period for these patients was 12.8 months, with a range of 0.3-30.6 months. Comorbidities were present in 21%-65% of the patients. Hypertension, hyperlipidemia, diabetes mellitus, obstructive sleep apnea, GERD, and asthma either resolved or improved in 80%-100% of the patients. Arthritis, back or extremity pain, and depression also improved but to a lesser extent, in 52%-73% of patients. Our patients' quality of life greatly improved even at 6 weeks postoperatively in 35% of the patients, and this increased to >80% after 18 months. CONCLUSIONS: Gastric bypass surgery for the treatment of morbidly obese patients has a profound positive impact on obesity-related comorbidities. Also, patients' quality of life is dramatically improved in the majority of patients when compared with their preoperative status.
BACKGROUND:Obesity is associated with multiple comorbidities, including hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus, obstructive sleep apnea, osteoarthritis, back/extremity pain, gastroesophageal reflux disease (GERD), asthma, and depression. Surgical weight loss can markedly improve if not resolve many of these comorbidities. METHODS: This was a retrospective study of 400 consecutive gastric bypass patients, analyzing postoperative resolution or improvement of obesity-related comorbidities. RESULTS: Mean follow-up period for these patients was 12.8 months, with a range of 0.3-30.6 months. Comorbidities were present in 21%-65% of the patients. Hypertension, hyperlipidemia, diabetes mellitus, obstructive sleep apnea, GERD, and asthma either resolved or improved in 80%-100% of the patients. Arthritis, back or extremity pain, and depression also improved but to a lesser extent, in 52%-73% of patients. Our patients' quality of life greatly improved even at 6 weeks postoperatively in 35% of the patients, and this increased to >80% after 18 months. CONCLUSIONS: Gastric bypass surgery for the treatment of morbidly obesepatients has a profound positive impact on obesity-related comorbidities. Also, patients' quality of life is dramatically improved in the majority of patients when compared with their preoperative status.
Authors: Mohamed R Ali; David S Tichansky; Shanu N Kothari; Corrigan L McBride; Adolfo Z Fernandez; Harvey J Sugerman; John M Kellum; Luke G Wolfe; Eric J DeMaria Journal: Surg Endosc Date: 2009-06-11 Impact factor: 4.584
Authors: Marie-Pierre St-Onge; Michael A Grandner; Devin Brown; Molly B Conroy; Girardin Jean-Louis; Michael Coons; Deepak L Bhatt Journal: Circulation Date: 2016-09-19 Impact factor: 29.690
Authors: Mary Lisa Pories; Jennifer Hodgson; Mary Ann Rose; John Pender; Natalia Sira; Melvin Swanson Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: Enrique Arias; Pedro R Martínez; Vicky Ka Ming Li; Samuel Szomstein; Raul J Rosenthal Journal: Obes Surg Date: 2009-03-12 Impact factor: 4.129
Authors: Nicole M Gilbertson; Andrew S Paisley; Sibylle Kranz; Arthur Weltman; Jennifer L Kirby; Peter T Hallowell; Steven K Malin Journal: Obes Surg Date: 2017-12 Impact factor: 4.129